Symptoms initially lessened but rebound from day 8. Still testing positive in rapid test on day 10 with painful sinus congestion, chills and feverish.; This spontaneous case was reported by a non-health professional and describes the occurrence of COVID-19 (Symptoms initially lessened but rebound from day 8. Still testing positive in rapid test on day 10 with painful sinus congestion, chills and feverish.) in a  patient of an unknown age and gender who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch nos. 027H21B, 025C21A and 025B21A) for COVID-19 vaccination.     Patient had allergic reaction to MRI contrast dye.  Concurrent medical conditions included Contrast media allergy (MRI contrast dye).   On 05-Apr-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On 04-May-2021, received second dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) dosage was changed to 1 dosage form. On 18-Nov-2021, received third dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) dosage was changed to 1 dosage form. In May 2022, the patient experienced COVID-19 (Symptoms initially lessened but rebound from day 8. Still testing positive in rapid test on day 10 with painful sinus congestion, chills and feverish.). The patient was treated with NIRMATRELVIR, RITONAVIR (PAXLOVID) from 13-May-2022 to 15-May-2022 for COVID-19 treatment, at an unspecified dose and frequency. At the time of the report, COVID-19 (Symptoms initially lessened but rebound from day 8. Still testing positive in rapid test on day 10 with painful sinus congestion, chills and feverish.) had not resolved.      DIAGNOSTIC RESULTS (normal ranges are provided in parenthesis if available): In May 2022, SARS-CoV-2 test: positive (Positive) Positive.         Concomitant medication was not reported. The patient was not taking any other medications/products within 2 weeks of starting COVID-19 treatment.  Company Comment: This is a spontaneous case concerning  a patient of unknown age and gender, with no relevant medical history, who experienced the unexpected non-serious event of Covid-19. The event occurred on an unspecified date of May 2021, after the second dose of mRNA-1273 COVID 19 Vaccine, which was administered on May 4, 2021. Patient tested positive for SARS-CoV-2 test. Patient was treated with nirmatrelvir tablets; ritonavir tablets from May 13, 2022- May 15, 2022, at an unspecified dose and frequency. The events were reported as not resolved. The benefit-risk relationship of mRNA-1273 COVID 19 Vaccine, is not affected by this report.; Sender's Comments: Company Comment: This is a spontaneous case concerning  a patient of unknown age and gender, with no relevant medical history, who experienced the unexpected non-serious AESI event of Covid-19. The event occurred on an unspecified date of May 2021, after the second dose of mRNA-1273 COVID 19 Vaccine, which was administered on May 4, 2021. Patient tested positive for SARS-CoV-2 test. Patient was treated with nirmatrelvir tablets; ritonavir tablets from May 13, 2022- May 15, 2022, at an unspecified dose and frequency. The events were reported as not resolved. The benefit-risk relationship of mRNA-1273 COVID 19 Vaccine, is not affected by this report.